SFF
The journey towards developing and launching new antibiotics confronts obstacles that demand careful consideration. These challenges encompass both the scientific complexities and the intricacies of navigating an anti-AMR market landscape.
Progressing the antibiotics through the clinical stages efficiently and preparing for a successful commercial launch demanded a unified approach. Recognising the complexity of this endeavour, Innoviva Specialty Therapeutics and ACS Dobfar found themselves in need of comprehensive and integrated support that would not only expedite the development process but also ensure the optimal positioning of these vital antibiotics in the market.
To read our case study please fill in your details below: